243 related articles for article (PubMed ID: 26458165)
1. Immunopathogenesis of inflammatory bowel diseases: functional role of T cells and T cell homing.
Zundler S; Neurath MF
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S19-28. PubMed ID: 26458165
[TBL] [Abstract][Full Text] [Related]
2. Potential role of nutraceutical compounds in inflammatory bowel disease.
Larussa T; Imeneo M; Luzza F
World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
[TBL] [Abstract][Full Text] [Related]
3. Lymphatic dysregulation in intestinal inflammation: new insights into inflammatory bowel disease pathomechanisms.
Becker F; Yi P; Al-Kofahi M; Ganta VC; Morris J; Alexander JS
Lymphology; 2014 Mar; 47(1):3-27. PubMed ID: 25109166
[TBL] [Abstract][Full Text] [Related]
4. Disrupted regulatory T cell homeostasis in inflammatory bowel diseases.
Pedros C; Duguet F; Saoudi A; Chabod M
World J Gastroenterol; 2016 Jan; 22(3):974-95. PubMed ID: 26811641
[TBL] [Abstract][Full Text] [Related]
5. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
[TBL] [Abstract][Full Text] [Related]
6. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory Bowel Disease.
Prog Drug Res; 2016; 71():117-22. PubMed ID: 26939275
[TBL] [Abstract][Full Text] [Related]
8. Role of interleukin-22 in inflammatory bowel disease.
Li LJ; Gong C; Zhao MH; Feng BS
World J Gastroenterol; 2014 Dec; 20(48):18177-88. PubMed ID: 25561785
[TBL] [Abstract][Full Text] [Related]
9. miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation.
Xu XM; Zhang HJ
World J Gastroenterol; 2016 Feb; 22(7):2206-18. PubMed ID: 26900285
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
11. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
Zundler S; Neurath MF
Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
[TBL] [Abstract][Full Text] [Related]
12. Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases.
Evans-Marin HL; Cong Y
Inflamm Allergy Drug Targets; 2015; 14(1):4-12. PubMed ID: 26296210
[TBL] [Abstract][Full Text] [Related]
13. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.
Quetglas EG; Mujagic Z; Wigge S; Keszthelyi D; Wachten S; Masclee A; Reinisch W
World J Gastroenterol; 2015 Nov; 21(44):12519-43. PubMed ID: 26640330
[TBL] [Abstract][Full Text] [Related]
14. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.
Stefanelli T; Malesci A; Repici A; Vetrano S; Danese S
Curr Drug Targets; 2008 May; 9(5):413-8. PubMed ID: 18473770
[TBL] [Abstract][Full Text] [Related]
15. Selenium and inflammatory bowel disease.
Kudva AK; Shay AE; Prabhu KS
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(2):G71-7. PubMed ID: 26045617
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease.
Farzaei MH; Bahramsoltani R; Abdolghaffari AH; Sodagari HR; Esfahani SA; Rezaei N
Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):745-58. PubMed ID: 26799847
[TBL] [Abstract][Full Text] [Related]
17. When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.
Krishnareddy S; Swaminath A
World J Gastroenterol; 2014 Feb; 20(5):1139-46. PubMed ID: 24574790
[TBL] [Abstract][Full Text] [Related]
18. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
Zundler S; Becker E; Schulze LL; Neurath MF
Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
[TBL] [Abstract][Full Text] [Related]
19. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
20. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease.
Mayer L; Eisenhardt D
J Clin Invest; 1990 Oct; 86(4):1255-60. PubMed ID: 2145321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
